Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDWYUN)

• Drug Name: HBI-8000 Drug Info
• Synonyms: CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Registered	[1]
Solid tumour/cancer	2A00-2F9Z	Registered	[2] , [3]
Melanoma	2C30	Phase 1/2	[1] , [4]
Merkel cell carcinoma	2C34	Phase 1/2	[1]
Renal cell carcinoma	2C90	Phase 1/2	[1]

• Cross-matching ID:
  PubChem CID: 12136798
  ChEBI ID: CHEBI:135918
  CAS Number: CAS 1616493-44-7
  TTD Drug ID: DMDWYUN

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[7]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[8]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[9]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[10]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[1]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[12]
PDX-101	DM6OC53	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[1]

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Cutaneous T-cell lymphoma	2B01	Approved	[13]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[14]
Panobinostat	DM58WKG	Multiple myeloma	2A83	Approved	[13]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[15]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[16]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[10]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[17]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[13]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[18]
Sodium butyrate	DMKNIVG	Acute myeloid leukaemia	2A60	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1] , [4]
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Modulator	[5]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8305).
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025931)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [6] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [7] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [10] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [11] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [12] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [13] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [14] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [15] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [16] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [17] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [18] 2011 Pipeline of 4SC AG.
• [19] Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.